Hepatitis

No cure for hepatitis B and D without targeting integrated viral DNA?

RNA interference (RNAi) is a novel concept to target transcripts derived from HBV covalently closed circular DNA. The study by Wooddell et al. investigates the RNAi-based therapy ARC-520 in patients and chimpanzees with chronic HBV infection and uncovers HBV DNA integration as a crucial source of hepatitis B surface antigen, which has not been considered in current strategies to accomplish HBV cure.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Schematic illustration of how ARC-520 targets HBV.

References

  1. 1

    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370–398 (2017).

  2. 2

    Bock, C. T. et al. Structural organization of the hepatitis B virus minichromosome. J. Mol. Biol. 307, 183–196 (2001).

    CAS  Article  PubMed  Google Scholar 

  3. 3

    Seeger, C. & Mason, W. S. Molecular biology of hepatitis B virus infection. Virology 479–480, 672–686 (2015).

    Article  PubMed  Google Scholar 

  4. 4

    Cornberg, M. et al. The role of quantitative hepatitis B surface antigen revisited. J. Hepatol. 66, 398–411 (2017).

    CAS  Article  PubMed  Google Scholar 

  5. 5

    Testoni, B., Durantel, D. & Zoulim, F. Novel targets for hepatitis B virus therapy. Liver Int. 37 (Suppl. 1), 33–39 (2017).

    CAS  Article  PubMed  Google Scholar 

  6. 6

    Bertoletti, A. & Ferrari, C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61, 1754–1764 (2012).

    CAS  Article  PubMed  Google Scholar 

  7. 7

    Wooddell, C. I. et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl Med. 9, eaan0241 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8

    Höner zu Siederdissen, C., Maasoumy, B. & Cornberg, M. What is new on HBsAg and other diagnostic markers in HBV infection. Best Pract. Res. Clin. Gastroenterol. 31, 281–289 (2017).

    Article  PubMed  Google Scholar 

  9. 9

    Allweiss, L. et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut https://doi.org/10.1136/gutjnl-2016-312162 (2017).

    Article  PubMed  Google Scholar 

  10. 10

    Bogomolov, P. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J. Hepatol. 65, 490–498 (2016).

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank F. Rinker for drafting the figure and T. Bock for critical review of the manuscript.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Markus Cornberg or Michael P. Manns.

Ethics declarations

Competing interests

M.C. received payments for lectures and consultation from Bristol-Myers Squibb, Gilead Sciences and Roche. M.M. received payments for lectures, consultation and trial support from Bristol-Myers Squibb, CureVac, Gilead Sciences, Glaxo Smith Kline, MSD, Novartis and Roche.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cornberg, M., Manns, M. No cure for hepatitis B and D without targeting integrated viral DNA?. Nat Rev Gastroenterol Hepatol 15, 195–196 (2018). https://doi.org/10.1038/nrgastro.2017.185

Download citation

Further reading